Loading organizations...
Sangon Biotech operates as a comprehensive platform delivering essential products and services across the life sciences spectrum. The company provides a full suite of research and development tools, alongside critical upstream raw materials for industrial-scale biopharmaceutical production. Notably, Sangon Biotech stands as one of the largest DNA synthesis manufacturers globally, offering extensive capabilities in DNA and RNA synthesis, peptide synthesis, protein expression and purification, and antibody preparation.
The company's origins trace back to 1995 with the establishment of Shanghai Sangon Biotechnology Service Co., Ltd., followed by the formal incorporation of Sangon Biotech (Shanghai) Co., Ltd. in 2003. Founder Qisong Wang initiated the enterprise with the insight that China's nascent life science research and industrial sectors required robust, domestic infrastructure for fundamental biological tools, spearheading the creation of China's first commercial DNA synthesis production line.
Sangon Biotech’s extensive clientele includes numerous universities, research institutions, hospitals, and a broad array of pharmaceutical and biotechnology companies. These customers leverage Sangon's offerings for both basic scientific inquiry and industrial applications, spanning in vitro diagnostics, contract research, genetic diagnostics, and agricultural biotechnology. The company envisions continued expansion as a global leader, consistently supporting and advancing biological research and innovation worldwide.
Sangon Biotech has raised $6.0M across 1 funding round.
Sangon Biotech has raised $6.0M in total across 1 funding round.
Sangon Biotech has raised $6.0M in total across 1 funding round.
Sangon Biotech's investors include Qiming Venture Partners.
Sangon Biotech is a leading biotechnology company based in Shanghai, China, primarily focused on providing life science products and services, especially in DNA synthesis and molecular biology. It serves a broad customer base including over 7,000 academic institutions and more than 40,000 biotech, biopharma, and in vitro diagnostics (IVD) companies across China. Sangon Biotech offers a wide range of products such as oligonucleotide synthesis, DNA sequencing, next-generation sequencing, and other molecular biology services, positioning itself as a one-stop-shop for life science research needs. The company is recognized for competitive pricing, original manufacturing capabilities, and strict quality control, contributing to its rapid growth and leadership in the Chinese life science tools market, which grows annually by about 15% excluding COVID-19 effects[1][2][3].
Founded in 2003 in Shanghai, Sangon Biotech began with a focus on oligonucleotide synthesis, a critical technology for genetic research and biotechnology. Over time, it expanded its product portfolio to include various life science tools and services, evolving into a comprehensive supplier for molecular biology research. The company’s growth was driven by continuous investment in research and development and a commitment to quality and innovation. Early traction came from establishing itself as a reliable original manufacturer with competitive pricing and a broad product range, which helped it build a large and diverse customer base in academia and industry[1][3][6].
Sangon Biotech rides the global trend of expanding genomics and molecular biology research, fueled by advances in DNA synthesis and sequencing technologies. The timing is favorable due to increasing demand for life science tools in China’s rapidly growing biotech sector and the global push for precision medicine and biotechnology innovation. Market forces such as government support for biotech, rising R&D investments, and the need for localized manufacturing capacity in China work in Sangon’s favor. By providing affordable, high-quality products and integrating digital lab solutions through partnerships, Sangon influences the broader ecosystem by enabling faster scientific discovery and supporting the growth of biotech startups and research institutions in China[2][4].
Looking ahead, Sangon Biotech is poised to deepen its technological leadership by leveraging digital transformation in laboratories and expanding its product offerings. Trends such as personalized medicine, synthetic biology, and AI-driven biotech research will shape its journey. The company’s collaboration with global technology providers suggests a focus on innovation and efficiency gains, which could enhance its competitive edge and market share. Sangon’s influence is likely to grow as it continues to support China’s ambitions in biotechnology, potentially expanding its footprint internationally while maintaining strong domestic leadership[4][2]. This trajectory ties back to its founding mission of being a comprehensive, innovative provider in the life sciences sector.
Sangon Biotech has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in June 2010.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2010 | $6.0M Series A | Qiming Venture Partners |